Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RiMO Therapeutics
Elk Grove Village, Illinois, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
RiMO Therapeutics developed a nanotechnology platform using nMOFs to enhance the effect of radiotherapy. Their lead program, RiMO-301, entered Phase 1 trials for head and neck cancer. Preclinical studies indicated the platform could increase tumor response and enhance the benefit of immunotherapy with lower toxicity. As of 2018, RiMO was enrolling patients in clinical trials, but has since been acquired and incorporated into Coordination Pharmaceuticals.[2][3][5][1]
- Therapeutic areas
- Oncology
- Modalities
- NanoparticleSmall molecule
- Industry
- Biotech
02
Partnerships
University of Chicago
Beyond the preview
Go deeper on RiMO Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RiMO Therapeutics.